Figure 3. Evaluating FDA-approved medications identifies new modifiers of the nicotine response using larval zebrafish locomotion.

Zebrafish pretreated with medication overnight and challenged with 20 μM nicotine. Category (i) compounds: no attenuation of the nicotine response and no toxicity with overnight incubation in the drug up to 1 mM concentrations. Category (ii) compounds: no attenuation of the nicotine response, but toxicity was observed at the next highest dose evaluated. Category (iii) compounds: significantly attenuated the nicotine response and the cinnamon oil and/or mustard oil response. Category (iv) compounds: significantly attenuated the locomotor response to nicotine, but not to cinnamon oil or mustard oil responses. Current Treatment  =  FDA-approved medications for smoking cessation. n≥30 larvae per condition; *  = p<0.05; † = 0.05<p<0.1; Students t-test.